Drugs / SCB-2023B
last change Oct 2024 re-read 2 minutes ago

SCB-2023B

Vaccine

Developed for
COVID-19
Investigated by
Clover Biopharmaceuticals AUS Pty

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06567457 Oct 2023 → Sep 2024 COVID-19 Clover Biopharmaceuticals AUS Pty Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SCB-2023B ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567457
Modality Vaccine “SCB-2023B vaccineNCT06567457